Fig. 1

Changes in the mean BCVA in patients with nAMD treated with brolucizumab every 6 weeks during induction therapy. The mean BCVA was significantly improved after the second IVBr injection. BCVA = best-corrected visual acuity. *p < 0.05, **p < 0.005.